Related Experiment Video

Updated: Oct 6, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

[Attitude of patients after myocardial infarction to long-term therapy with beta blockers]

E A Shutemova, A I Zhukova, L V Lebedeva

    Klinicheskaia Meditsina
    |June 23, 2001
    PubMed

    Insights

    Most patients stopped taking beta-blockers (BB) within a year of myocardial infarction due to patient rejection and physician concerns. Improved understanding of BB benefits is crucial for secondary prevention.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Public Health

    Context:

    • Myocardial infarction (MI) survivors require long-term management for secondary prevention.
    • Beta-blockers (BB) are a cornerstone therapy shown to reduce mortality post-MI.
    • Patient adherence and physician prescribing patterns significantly impact long-term treatment success.

    Purpose:

    • To investigate patient and physician attitudes towards long-term beta-blocker (BB) therapy after myocardial infarction (MI).
    • To identify barriers to sustained BB use in the year following an MI.
    • To understand physician perspectives on prescribing and managing long-term BB treatment.

    Summary:

    • A 12-month follow-up study tracked 107 patients post-MI regarding their beta-blocker (BB) intake.
    • Only 22% of patients continued BB treatment, primarily due to patient non-adherence.
    • Physician-related factors included overestimation of side effects, reluctance for continuous patient care, and insufficient knowledge of BB's role in secondary prevention.

    Impact:

    • Low adherence to beta-blockers (BB) post-myocardial infarction (MI) highlights a gap in secondary prevention strategies.
    • Addressing patient rejection and physician-related barriers is essential for improving long-term cardiovascular outcomes.
    • Enhanced physician education on BB efficacy and management can optimize post-MI care and reduce event recurrence.

    Related Concept Videos

    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Myocarditis III: Medical Management01:14

    Myocarditis III: Medical Management

    Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
    Angina V: Nursing Management01:20

    Angina V: Nursing Management

    Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
    Acute Coronary Syndrome IV: Interprofessional Care01:28

    Acute Coronary Syndrome IV: Interprofessional Care

    IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
    Myocarditis IV: Nursing Management01:22

    Myocarditis IV: Nursing Management

    Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

    β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...